Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kura OncologyKURA +4.37%28 Debt-to-Equity is 0.23 as of Mar. 2026, which is 475% above its 10-year median of 0.04. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 966 Biotechnology companies, Kura Oncology ranks worse than 58.07% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kura Oncology's Debt-to-Equity or its related term are showing as below:
KURA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.23
Current: 0.23
During the past 12 years, the highest Debt-to-Equity Ratio of Kura Oncology was 0.23. The lowest was 0.01. And the median was 0.04.
KURA's Debt-to-Equity is ranked worse than 58.07% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs KURA: 0.23
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kura Oncology Debt-to-Equity Related Terms
Kura Oncology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kura Oncology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KURA vs PHAT, GERN, JANX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kura Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kura Oncology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kura Oncology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kura Oncology (KURA) has a Debt-to-Equity of 0.23 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kura Oncology and its competitors. This is 475% above median its historical median of 0.04. Over the past decade, Kura Oncology's Debt-to-Equity has ranged from 0.01 to 0.23. According to the industry distribution chart, Kura Oncology ranks #561 out of 966 companies in the Biotechnology industry, placing it in the top 58.1%.
Is Kura Oncology's Debt-to-Equity too high?
Kura Oncology's current Debt-to-Equity of 0.23 is 475% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.23. The Biotechnology industry median Debt-to-Equity is 0.16. Kura Oncology's value of 0.23 is 43.8% above this industry median. Based on the distribution chart, Kura Oncology ranks #561 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Debt-to-Equity compare to PHAT and GERN?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #561 out of 966 companies for Debt-to-Equity. This places Kura Oncology in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Kura Oncology's value of 0.23 is 43.8% above this benchmark. Historically, Kura Oncology's own Debt-to-Equity has ranged from 0.01 to 0.23 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Kura Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kura Oncology's current Debt-to-Equity of 0.23 is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kura Oncology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kura Oncology's current Debt-to-Equity is 0.23, which is 475% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (KURA) has a current Debt-to-Equity of 0.23. The current Debt-to-Equity is 0.23, which is 475% above median its 10-year median of 0.04 and 43.8% above the Biotechnology industry median of 0.16. Kura Oncology's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kura Oncology (KURA), the current Debt-to-Equity is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
28GF Score
Get the complete analysis for KURA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KURA has been successfully added to your 
